Relevant Articles About Liver Cancer Research and Clinical Trials
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Privacy Policy
KEY TAKEAWAYS The study aimed to investigate changes in cervical screening, excision treatments, and cancer incidence. Researchers noticed a decrease in appointments for older and rural patients with cervical cancer. Lavinia Balan and the team aimed to perform a...
KEY TAKEAWAYS The study aimed to investigate NAT10's role and mechanisms in DLBCL using clinical samples and various assays. The results showed the essential role of ac4C RNA modification mediated by NAT10 in DLBCL and provided insights into novel epigenetic-based...
KEY TAKEAWAYS The study aimed to analyze psychotropic medication and mental health service use 5 years before and after prostate cancer diagnosis. The results indicated increased psychotropic medication and mental health service use around prostate cancer...
The IMbrave150 phase 3 trial aimed to investigate etiological impact on AB-treated HCC patients, consolidating with prior lenvatinib studies. The result concluded that …
An observational study aimed to bridge the gap between research and clinical practice by demonstrating the feasibility and practicality of scRNA-seq for primary …
The phase 1 study analyzed FLC-Vac safety and immunogenicity with ipilimumab and nivolumab in patients with fibrolamellar carcinoma. The study showed vaccine safety, …
Background Melanoma, the most lethal form of skin cancer, has undergone a transformative treatment shift with the advent of checkpoint blockade immunotherapy (CBI). Understanding the intricate network of immune cells infiltrating the tumor and orchestrating the …
Background Immune-related hepatitis (irHepatitis) is a relatively common immune-related adverse event (irAE) of checkpoint inhibitors. Often, it responds well to steroids; however, in refractory cases, further therapy is needed. Anti-tumor necrosis factor (TNF) antibodies are used …
Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …